Bridgepoint Group Plc (8XW) Price & Analysis

Bridgepoint Group plc, formerly Bridgepoint Group Limited, is a financial institution specializing in both private equity and private credit. The firm deploys capital across diverse investment strategies, including growth capital, buyouts, syndicated debt, infrastructure financing, direct lending, and various private credit opportunities. It targets companies ranging from lower mid-market and middle market to small mid-cap and small-cap segments. Bridgepoint's investment focus spans a wide array of sectors. These include advanced industrials, automation, agricultural sciences, and businesses facilitating the energy transition. It also actively invests in business services, financial services, professional services, testing, inspection, and certification (TIC), and information services. Within the consumer domain, the firm backs digital brands, video games, and wellbeing products. Additionally, Bridgepoint has a significant presence in healthcare, particularly in pharmaceuticals, Med-Tech products, and outsourced Med-Tech services. Geographically, the firm primarily seeks opportunities across the United Kingdom, New York, Germany, Austria, Switzerland, Spain, France, and the Nordic region. Equity investments generally range from £4.77 million (approximately $5.91 million) to €300 million (around $348.8 million). Specifically, commitments for small mid-cap companies are typically between £40 million ($49.54 million) and £125 million ($154.82 million), while small-cap investments are usually between £10 million ($12.39 million) and £25 million ($30.96 million). Bridgepoint focuses on businesses with an enterprise value ranging from €10 million (about $10.74 million) to €1 billion (approximately $1.07 billion). Established in 1985, Bridgepoint Group plc is headquartered in London, United Kingdom, and maintains a global operational presence with additional offices across North America, Asia, and Europe.